PBAC Public Summary Documents – November 2018
Page last updated: 19 July 2019
Public Summary Documents relating to the November 2018 PBAC meeting.
- Alemtuzumab: Solution concentrate for I.V. infusion 12 mg in 1.2 mL; Lemtrada®
- Amino Acids-Synthetic, Formula: Oral powder 400 g (Neocate Junior Vanilla); Neocate Junior® Vanilla
- Apalutamide: Tablet 60 mg; Erlyand®
- Botulinum Toxin Type A: Lyophilised powder for injection 100 units; Botox®
- Brentuximab Vedotin: Powder for I.V. infusion 50 mg; Adcetris®
- Buprenorphine: Injection 8 mg in 0.16 mL pre-filled syringe, Injection 16 mg in 0.32 mL pre-filled syringe, Injection 24 mg in 0.48 mL pre-filled syringe, Injection 32 mg in 0.64 mL pre-filled syringe, Injection 64 mg in 0.18 mL pre-filled syringe, Injection 96 mg in 0.27 mL pre-filled syringe, Injection 128 mg in 0.36 mL pre-filled syringe; Buvidal®
- Carfilzomib: Powder for injection 30 mg, Powder for injection 60 mg; Kyprolis®
- Clostridium Botulinum Type A Toxin – Haemagglutinin C Complex (Lower Limb): Lyophilised powder for I.M. injection 300 units, Lyophilised powder for I.M. injection 500 units; Dysport®
- Clostridium Botulinum Type A Toxin – Haemagglutinin C Complex (Upper Limb): Lyophilised powder for I.M. injection 300 units, Lyophilised powder for I.M. injection 500 units; Dysport®
- Crisaborole: Ointment containing crisaborole 20 mg per g, 60 g; Staquis®
- Denosumab: Injection 120 mg in 1.7 mL; Xgeva®
- Durvalumab: Solution for I.V. infusion 120 mg in 2.4 mL, Solution for I.V. infusion 500 mg in 10 mL; Imfinzi®
- Encorafenib and Binimetinib: encorafenib: capsule 50 mg, capsule 75 mg; binimetinib: tablet 15 mg; Braftovi® and Mektovi®
- Etanercept: Injection 50 mg in 1 mL single use auto-injector, 4; Injections 50 mg in 1 mL single use pre-filled syringes, 4; Brenzys®
- Ferric Carboxymaltose: Injection 1 g (iron) in 20 mL; Ferinject®
- Fluticasone Propionate With Eformoterol: Pressurised inhalation containing fluticasone propionate 50 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses; Pressurised inhalation containing fluticasone propionate 125 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses; Pressurised inhalation containing fluticasone propionate 250 micrograms with formoterol fumarate dihydrate 10 micrograms per dose, 120 doses; Flutiform® 50/5, 125/5, 250/10
- Follitropin Alfa With Lutropin Alfa: Injection 900 I.U., 450 I.U. in 1.44 mL multi-dose cartridge; Pergoveris®
- Glycomacropeptide And Essential Amino Acids With Vitamins And Minerals: Oral liquid 250 mL, 30 (PKU Glytactin RTD 15 Lite); PKU Glytactin RTD 15 LITE®
- Glycomacropeptide Formula With Docosahexaenoic Acid With Low Phenylalanine: Sachets containing oral powder 33.3 g, 16 (PKU GMPro); PKU GMPro®
- Hypromellose: eye drops 3 mg per mL, 10 mL; In a Wink Moisturising Genteal®
- Inactivated Quadrivalent Influenza Vaccine (Split Virion): Injection 0.5mL in pre-filled syringe; Afluria® Quad
- Inotuzumab Ozogamicin: Powder for I.V. infusion 1 mg; Besponsa®
- Insulin Aspart: Injections (human analogue), pre filled pen, 100 units per mL, 3mL; Injections (human analogue), vial, 100 units per mL, 10 mL; Injections (human analogue), cartridges, 100 units per mL, 3 mL; Fiasp®
- Isotretinoin: Capsule 5 mg; Oratane®
- Lacosamide: Tablet 50 mg, Tablet 100 mg, Tablet 150 mg, Tablet 200 mg, Oral liquid 10 mg per mL, 200 mL ; Vimpat®
- Lenvatinib: Capsule 4 mg (as mesilate); Lenvima®
- Nivolumab And Ipilimumab: nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion, 100 mg in 10 mL; ipilimumab: Injection concentrate for I.V. infusion, 50 mg in 10 mL, Injection concentrate for I.V. infusion, 200 mg in 40 mL; Opdivo® and Yervoy®
- Obeticholic Acid: Tablet 5 mg, Tablet 10 mg; Ocaliva®
- Osimertinib: Tablet 40 mg, Tablet 80 mg; Tagrisso®
- Pembrolizumab: Powder for injection 50 mg, Solution concentrate for I.V. infusion, 100 mg in 4 mL; Keytruda®
- Pembrolizumab (melanoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Pembrolizumab (NSCLC): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Pembrolizumab (PMBCL): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Pneumococcal Polysaccharide Conjugate Vaccine, 13-Valent Adsorbed: Injection 0.5 mL in pre-filled syringe; Prevenar-13®
- Ponatinib: Tablet 15 mg (as hydrochloride), Tablet 45 mg (as hydrochloride); Iclusig®
- Quadrivalent Influenza Vaccines: Injection 0.5 mL in pre-filled syringe; Afluria® Quad; FluQuadri®; Fluarix Tetra®
- Regorafenib: Tablet 40 mg (as monohydrate); Stivarga®
- Riluzole: Oral liquid 50 mg per 10 mL, 300 mL; Teglutik®
- Rivaroxaban: Tablet 10 mg; Xarelto®
- Romosozumab: Injection 105 mg in 1.17 mL pre-filled pen; Evenity®
- Safinamide: Tablet 50 mg, Tablet 100 mg; Xadago®
- Sapropterin: Tablet (soluble) containing sapropterin dihydrochloride 100 mg; Kuvan®
- Sarilumab: Injection 200 mg in 1.14 mL pre-filled syringe, Injection 150 mg in 1.14 mL pre-filled syringe; Kevzara®
- Testosterone: Transdermal gel (pump pack) 2% w/w enhanced permeation (EP) gel; Testavan®
- Tiotropium: Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations); Spiriva® Respimat®
- Tocilizumab: Injection 162 mg in 0.9 mL pre-filled pen, Injection 162 mg in 0.9 mL pre-filled syringe; Actemra®
- Tofacitinib: Tablet 5 mg; Xeljanz®
- Varicella Zoster Virus Recombinant Vaccine: injection [1 vial] & adjuvant substance diluent [0.5 mL vial], 1 pack; Shingrix®
- Venetoclax: Tablet 10 mg, Tablet 50 mg, Tablet 100 mg; Venclexta®
The following Public Summary Documents have been updated based on outcomes from the November 2018 meeting.
